Is SIBN or ESTA more profitable?

SiBone has a net margin of -8.10% compared to Establishment Labs' net margin of -19.05%. SiBone's return on equity of -9.56% beat Establishment Labs' return on equity. Company Net Margins Return on Equity Return on Assets SiBone -8.10% -9.56% -7.06% Establishment Labs -19.05% -218.77% -12.31%

Does the media favor SIBN or ESTA?

In the previous week, Establishment Labs had 2 more articles in the media than SiBone. MarketBeat recorded 8 mentions for Establishment Labs and 6 mentions for SiBone. Establishment Labs' average media sentiment score of 1.35 beat SiBone's score of 1.31 indicating that Establishment Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Establishment Labs 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, WRBY or SIBN?

Warby Parker has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Warby Parker $871.91M 3.06 $1.64M $0.02 1,247.25 SiBone $200.93M 3.78 -$18.90M -$0.39 N/A

Is WRBY or SIBN more profitable?

Warby Parker has a net margin of 0.15% compared to SiBone's net margin of -8.10%. Warby Parker's return on equity of 2.30% beat SiBone's return on equity. Company Net Margins Return on Equity Return on Assets Warby Parker 0.15% 2.30% 1.18% SiBone -8.10% -9.56% -7.06%

Does the media prefer WRBY or SIBN?

In the previous week, SiBone had 2 more articles in the media than Warby Parker. MarketBeat recorded 6 mentions for SiBone and 4 mentions for Warby Parker. SiBone's average media sentiment score of 1.31 beat Warby Parker's score of 1.26 indicating that SiBone is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Warby Parker 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SiBone 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, TMDX or SIBN?

TransMedics Group has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransMedics Group $605.49M 4.25 $190.29M $4.40 16.92 SiBone $200.93M 3.78 -$18.90M -$0.39 N/A

Does the media favor TMDX or SIBN?

In the previous week, TransMedics Group had 3 more articles in the media than SiBone. MarketBeat recorded 9 mentions for TransMedics Group and 6 mentions for SiBone. SiBone's average media sentiment score of 1.31 beat TransMedics Group's score of 0.92 indicating that SiBone is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SiBone 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, SIBN or LMAT?

LeMaitre Vascular has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 3.78 -$18.90M -$0.39 N/A LeMaitre Vascular $249.60M 9.05 $57.73M $2.71 36.48

Does the media prefer SIBN or LMAT?

In the previous week, SiBone had 4 more articles in the media than LeMaitre Vascular. MarketBeat recorded 6 mentions for SiBone and 2 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 1.84 beat SiBone's score of 1.31 indicating that LeMaitre Vascular is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LeMaitre Vascular 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better earnings and valuation, SIBN or AXGN?

AxoGen has higher revenue and earnings than SiBone. AxoGen is trading at a lower price-to-earnings ratio than SiBone, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 3.78 -$18.90M -$0.39 N/A AxoGen $238.11M 9.18 -$15.70M -$0.64 N/A

Is SIBN or AXGN more profitable?

SiBone has a net margin of -8.10% compared to AxoGen's net margin of -13.21%. SiBone's return on equity of -9.56% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -8.10% -9.56% -7.06% AxoGen -13.21% -9.63% -6.26%

Does the media refer more to SIBN or AXGN?

In the previous week, SiBone and SiBone both had 6 articles in the media. SiBone's average media sentiment score of 1.31 beat AxoGen's score of 1.00 indicating that SiBone is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AxoGen 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

SiBone (SIBN) Competitors

$17.05 +0.43 (+2.60%)

As of 04:00 PM Eastern

Compare

SIBN vs. ESTA, WRBY, TMDX, LMAT, and AXGN

Should you buy SiBone stock or one of its competitors? MarketBeat compares SiBone with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SiBone include Establishment Labs (ESTA), Warby Parker (WRBY), TransMedics Group (TMDX), LeMaitre Vascular (LMAT), and AxoGen (AXGN). These companies are all part of the "medical equipment" industry.

How does SiBone compare to Establishment Labs?

SiBone (NASDAQ:SIBN) and Establishment Labs (NASDAQ:ESTA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

SiBone has higher earnings, but lower revenue than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than SiBone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	3.78	-$18.90M	-$0.39	N/A
Establishment Labs	$211.08M	12.84	-$51.06M	-$1.49	N/A

SiBone presently has a consensus target price of $23.50, indicating a potential upside of 37.31%. Establishment Labs has a consensus target price of $90.43, indicating a potential downside of 1.83%. Given SiBone's stronger consensus rating and higher possible upside, analysts clearly believe SiBone is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Establishment Labs had 2 more articles in the media than SiBone. MarketBeat recorded 8 mentions for Establishment Labs and 6 mentions for SiBone. Establishment Labs' average media sentiment score of 1.35 beat SiBone's score of 1.31 indicating that Establishment Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Establishment Labs	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SiBone has a net margin of -8.10% compared to Establishment Labs' net margin of -19.05%. SiBone's return on equity of -9.56% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
Establishment Labs	-19.05%	-218.77%	-12.31%

98.1% of SiBone shares are held by institutional investors. Comparatively, 72.9% of Establishment Labs shares are held by institutional investors. 4.0% of SiBone shares are held by company insiders. Comparatively, 10.0% of Establishment Labs shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

SiBone has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Summary

SiBone beats Establishment Labs on 9 of the 16 factors compared between the two stocks.

How does SiBone compare to Warby Parker?

Warby Parker (NYSE:WRBY) and SiBone (NASDAQ:SIBN) are both medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

Warby Parker presently has a consensus price target of $29.82, indicating a potential upside of 19.54%. SiBone has a consensus price target of $23.50, indicating a potential upside of 37.31%. Given SiBone's stronger consensus rating and higher possible upside, analysts plainly believe SiBone is more favorable than Warby Parker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Warby Parker	0 Sell rating(s)	5 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.67
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Warby Parker has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Warby Parker	$871.91M	3.06	$1.64M	$0.02	1,247.25
SiBone	$200.93M	3.78	-$18.90M	-$0.39	N/A

93.2% of Warby Parker shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 16.8% of Warby Parker shares are owned by insiders. Comparatively, 4.0% of SiBone shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, SiBone had 2 more articles in the media than Warby Parker. MarketBeat recorded 6 mentions for SiBone and 4 mentions for Warby Parker. SiBone's average media sentiment score of 1.31 beat Warby Parker's score of 1.26 indicating that SiBone is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Warby Parker	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SiBone	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Warby Parker has a net margin of 0.15% compared to SiBone's net margin of -8.10%. Warby Parker's return on equity of 2.30% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Warby Parker	0.15%	2.30%	1.18%
SiBone	-8.10%	-9.56%	-7.06%

Warby Parker has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market. Comparatively, SiBone has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Summary

Warby Parker beats SiBone on 10 of the 16 factors compared between the two stocks.

How does SiBone compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and SiBone (NASDAQ:SIBN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

In the previous week, TransMedics Group had 3 more articles in the media than SiBone. MarketBeat recorded 9 mentions for TransMedics Group and 6 mentions for SiBone. SiBone's average media sentiment score of 1.31 beat TransMedics Group's score of 0.92 indicating that SiBone is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SiBone	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TransMedics Group has a net margin of 27.04% compared to SiBone's net margin of -8.10%. TransMedics Group's return on equity of 22.38% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	27.04%	22.38%	8.46%
SiBone	-8.10%	-9.56%	-7.06%

TransMedics Group presently has a consensus target price of $134.50, indicating a potential upside of 80.67%. SiBone has a consensus target price of $23.50, indicating a potential upside of 37.31%. Given TransMedics Group's higher possible upside, research analysts clearly believe TransMedics Group is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

TransMedics Group has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	4.25	$190.29M	$4.40	16.92
SiBone	$200.93M	3.78	-$18.90M	-$0.39	N/A

TransMedics Group has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market. Comparatively, SiBone has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

99.7% of TransMedics Group shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 6.9% of TransMedics Group shares are held by insiders. Comparatively, 4.0% of SiBone shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

TransMedics Group beats SiBone on 13 of the 15 factors compared between the two stocks.

How does SiBone compare to LeMaitre Vascular?

SiBone (NASDAQ:SIBN) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

SiBone has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

LeMaitre Vascular has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	3.78	-$18.90M	-$0.39	N/A
LeMaitre Vascular	$249.60M	9.05	$57.73M	$2.71	36.48

SiBone presently has a consensus target price of $23.50, indicating a potential upside of 37.31%. LeMaitre Vascular has a consensus target price of $112.60, indicating a potential upside of 13.91%. Given SiBone's stronger consensus rating and higher possible upside, equities research analysts clearly believe SiBone is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, SiBone had 4 more articles in the media than LeMaitre Vascular. MarketBeat recorded 6 mentions for SiBone and 2 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 1.84 beat SiBone's score of 1.31 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LeMaitre Vascular	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

LeMaitre Vascular has a net margin of 24.35% compared to SiBone's net margin of -8.10%. LeMaitre Vascular's return on equity of 15.36% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
LeMaitre Vascular	24.35%	15.36%	9.78%

98.1% of SiBone shares are held by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are held by institutional investors. 4.0% of SiBone shares are held by company insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

LeMaitre Vascular beats SiBone on 10 of the 16 factors compared between the two stocks.

How does SiBone compare to AxoGen?

SiBone (NASDAQ:SIBN) and AxoGen (NASDAQ:AXGN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

SiBone has a net margin of -8.10% compared to AxoGen's net margin of -13.21%. SiBone's return on equity of -9.56% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
AxoGen	-13.21%	-9.63%	-6.26%

SiBone has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, AxoGen has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

SiBone currently has a consensus target price of $23.50, suggesting a potential upside of 37.31%. AxoGen has a consensus target price of $46.50, suggesting a potential upside of 13.10%. Given SiBone's higher possible upside, analysts plainly believe SiBone is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

AxoGen has higher revenue and earnings than SiBone. AxoGen is trading at a lower price-to-earnings ratio than SiBone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	3.78	-$18.90M	-$0.39	N/A
AxoGen	$238.11M	9.18	-$15.70M	-$0.64	N/A

In the previous week, SiBone and SiBone both had 6 articles in the media. SiBone's average media sentiment score of 1.31 beat AxoGen's score of 1.00 indicating that SiBone is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AxoGen	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.1% of SiBone shares are owned by institutional investors. Comparatively, 80.3% of AxoGen shares are owned by institutional investors. 4.0% of SiBone shares are owned by company insiders. Comparatively, 2.4% of AxoGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

SiBone beats AxoGen on 8 of the 15 factors compared between the two stocks.

Get SiBone News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SIBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SIBN vs. The Competition

Export

Metric	SiBone	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$759.49M	$7.38B	$6.92B	$12.17B
Dividend Yield	N/A	1.33%	2.67%	9.81%
P/E Ratio	-43.91	48.49	27.12	23.76
Price / Sales	3.78	52.38	528.45	92.21
Price / Cash	N/A	26.30	26.39	46.67
Price / Book	4.18	6.85	10.45	6.16
Net Income	-$18.90M	$162.27M	$3.60B	$331.26M
7 Day Performance	-0.03%	-2.99%	-1.25%	-0.03%
1 Month Performance	-1.24%	-5.92%	-2.58%	-2.50%
1 Year Performance	-0.78%	-1.71%	18.50%	13.99%

SiBone Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SIBN SiBone	3.7105 of 5 stars	$17.12 +3.0%	$23.50 +37.3%	-3.7%	$759.49M	$200.93M	N/A	350	News Coverage Upcoming Earnings
ESTA Establishment Labs	2.0857 of 5 stars	$96.40 +3.2%	$90.43 -6.2%	+117.7%	$2.84B	$211.08M	N/A	1,004	News Coverage Positive News
WRBY Warby Parker	3.7387 of 5 stars	$24.37 -0.9%	$29.82 +22.4%	+0.6%	$2.61B	$871.91M	1,220.31	4,036	News Coverage Positive News Gap Up
TMDX TransMedics Group	4.5487 of 5 stars	$74.83 +1.8%	$134.50 +79.7%	-33.2%	$2.59B	$605.49M	17.01	210	Positive News Upcoming Earnings
LMAT LeMaitre Vascular	4.1411 of 5 stars	$101.11 -0.6%	$112.60 +11.4%	+16.0%	$2.31B	$249.60M	37.31	490	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SIBN) was last updated on 7/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SiBone (SIBN) Competitors

SIBN vs. ESTA, WRBY, TMDX, LMAT, and AXGN

How does SiBone compare to Establishment Labs?

Summary

How does SiBone compare to Warby Parker?

Summary

How does SiBone compare to TransMedics Group?

Summary

How does SiBone compare to LeMaitre Vascular?

Summary

How does SiBone compare to AxoGen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIBN vs. The Competition

SiBone Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SiBone (SIBN) Competitors

SIBN vs. ESTA, WRBY, TMDX, LMAT, and AXGN

How does SiBone compare to Establishment Labs?

Which has preferable valuation & earnings, SIBN or ESTA?

Do analysts prefer SIBN or ESTA?

Does the media favor SIBN or ESTA?

Is SIBN or ESTA more profitable?

Do insiders and institutionals believe in SIBN or ESTA?

Which has more volatility and risk, SIBN or ESTA?

Summary

How does SiBone compare to Warby Parker?

Do analysts recommend WRBY or SIBN?

Which has higher valuation & earnings, WRBY or SIBN?

Do institutionals and insiders have more ownership in WRBY or SIBN?

Does the media prefer WRBY or SIBN?

Is WRBY or SIBN more profitable?

Which has more risk & volatility, WRBY or SIBN?

Summary

How does SiBone compare to TransMedics Group?

Does the media favor TMDX or SIBN?

Is TMDX or SIBN more profitable?

Do analysts recommend TMDX or SIBN?

Which has better valuation & earnings, TMDX or SIBN?

Which has more risk and volatility, TMDX or SIBN?

Do institutionals & insiders believe in TMDX or SIBN?

Summary

How does SiBone compare to LeMaitre Vascular?

Which has more volatility and risk, SIBN or LMAT?

Which has better earnings and valuation, SIBN or LMAT?

Do analysts prefer SIBN or LMAT?

Does the media prefer SIBN or LMAT?

Is SIBN or LMAT more profitable?

Do institutionals and insiders believe in SIBN or LMAT?

Summary

How does SiBone compare to AxoGen?

Is SIBN or AXGN more profitable?

Which has more risk and volatility, SIBN or AXGN?

Do analysts recommend SIBN or AXGN?

Which has better earnings and valuation, SIBN or AXGN?

Does the media refer more to SIBN or AXGN?

Do institutionals & insiders hold more shares of SIBN or AXGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIBN vs. The Competition

SiBone Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools